Confidence from uncertainty - A multi-target drug screening method from robust control theory

BackgroundRobustness is a recognized feature of biological systems that evolved as a defence to environmental variability. Complex diseases such as diabetes, cancer, bacterial and viral infections, exploit the same mechanisms that allow for robust behaviour in healthy conditions to ensure their own continuance. Single drug therapies, while generally potent regulators of their specific protein/gene targets, often fail to counter the robustness of the disease in question. Multi-drug therapies offer a powerful means to restore disrupted biological networks, by targeting the subsystem of interest while preventing the diseased network from reconciling through available, redundant mechanisms. Modelling techniques are needed to manage the high number of combinatorial possibilities arising in multi-drug therapeutic design, and identify synergistic targets that are robust to system uncertainty.ResultsWe present the application of a method from robust control theory, Structured Singular Value or μ- analysis, to identify highly effective multi-drug therapies by using robustness in the face of uncertainty as a new means of target discrimination. We illustrate the method by means of a case study of a negative feedback network motif subject to parametric uncertainty.ConclusionsThe paper contributes to the development of effective methods for drug screening in the context of network modelling affected by parametric uncertainty. The results have wide applicability for the analysis of different sources of uncertainty like noise experienced in the data, neglected dynamics, or intrinsic biological variability.

[1]  Gil Alterovitz,et al.  The challenges of informatics in synthetic biology: from biomolecular networks to artificial organisms , 2010, Briefings Bioinform..

[2]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[3]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[4]  Shuangzhe Liu,et al.  Global Sensitivity Analysis: The Primer by Andrea Saltelli, Marco Ratto, Terry Andres, Francesca Campolongo, Jessica Cariboni, Debora Gatelli, Michaela Saisana, Stefano Tarantola , 2008 .

[5]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[6]  Louis H Philipson,et al.  Regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach. , 2007, American journal of physiology. Cell physiology.

[7]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[8]  D. Gillespie A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical Reactions , 1976 .

[9]  Reka Albert,et al.  Biological switches and clocks , 2008, Journal of The Royal Society Interface.

[10]  Pablo A. Iglesias,et al.  Quantifying robustness of biochemical network models , 2002, BMC Bioinformatics.

[11]  Leon D. Segal,et al.  Functions , 1995 .

[12]  Seth Michelson,et al.  In silico prediction of clinical efficacy. , 2006, Current opinion in biotechnology.

[13]  E. Petricoin,et al.  Proteins, drug targets and the mechanisms they control: the simple truth about complex networks , 2007, Nature Reviews Drug Discovery.

[14]  Onn Brandman,et al.  Feedback Loops Shape Cellular Signals in Space and Time , 2008, Science.

[15]  Jan Lankelma,et al.  Principles behind the multifarious control of signal transduction , 2004, The FEBS journal.

[16]  Philip E. Bourne,et al.  A Multidimensional Strategy to Detect Polypharmacological Targets in the Absence of Structural and Sequence Homology , 2010, PLoS Comput. Biol..

[17]  Francis J Doyle,et al.  Identifying fragilities in biochemical networks: robust performance analysis of Fas signaling-induced apoptosis. , 2008, Biophysical journal.

[18]  J. Lehár,et al.  High-order combination effects and biological robustness , 2008, Molecular systems biology.

[19]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[20]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[21]  robustness of , 2022 .

[22]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[23]  Pamela K. Kreeger,et al.  Cancer systems biology: a network modeling perspective , 2009, Carcinogenesis.

[24]  S. Pongor,et al.  Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[25]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[26]  G. Saidel,et al.  A computational model of adipose tissue metabolism: evidence for intracellular compartmentation and differential activation of lipases. , 2008, Journal of theoretical biology.

[27]  John C. Doyle Analysis of Feedback Systems with Structured Uncertainty , 1982 .

[28]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  F. Sams-Dodd Target-based drug discovery: is something wrong? , 2005, Drug discovery today.

[30]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[31]  John Quackenbush,et al.  Extracting biology from high-dimensional biological data , 2007, Journal of Experimental Biology.

[32]  Domitilla Del Vecchio,et al.  A method for determining the robustness of bio-molecular oscillator models , 2009, BMC Systems Biology.

[33]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[34]  C. Daub,et al.  BMC Systems Biology , 2007 .

[35]  M. Peitsch,et al.  The application of systems biology to drug discovery. , 2006, Current opinion in chemical biology.

[36]  Harvey M. Wagner,et al.  Global Sensitivity Analysis , 1995, Oper. Res..

[37]  Hiroaki Kitano,et al.  The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models , 2003, Bioinform..

[38]  E. Gilles,et al.  Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors , 2002, Nature Biotechnology.

[39]  J. Hopfield,et al.  From molecular to modular cell biology , 1999, Nature.

[40]  Xiaobo Zhou,et al.  Global Sensitivity Analysis , 2017, Encyclopedia of GIS.

[41]  G E Stein,et al.  Amoxicillin-potassium clavulanate, a beta-lactamase-resistant antibiotic combination. , 1984, Clinical pharmacy.

[42]  E W Jacobsen,et al.  Structural robustness of biochemical network models-with application to the oscillatory metabolism of activated neutrophils. , 2008, IET systems biology.

[43]  A. Sherman,et al.  A mathematical model of metabolic insulin signaling pathways. , 2002, American journal of physiology. Endocrinology and metabolism.

[44]  Ian Postlethwaite,et al.  Multivariable Feedback Control: Analysis and Design , 1996 .